Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission
Phase 3
Completed
- Conditions
- Plasmodium FalciparumAsymptomatic ParataemiaSub Patent Parasitaemia
- Interventions
- Drug: placebo tablet similar to active drug in shape and size
- Registration Number
- NCT00646126
- Lead Sponsor
- Tropical Medicine Research Institute
- Brief Summary
The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- All residents of the 8 villages
Exclusion Criteria
- Pregnancy
- History of allergy to sulfa drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS) 1:Active comparator sulfadoxine-pyrimethamine plus artesunate 2 placebo tablet similar to active drug in shape and size 2:placebo comparator
- Primary Outcome Measures
Name Time Method Parsitaemia detected during the transmission season among dry season PCR negative persons in the intervention and control villages October to December 2006
- Secondary Outcome Measures
Name Time Method 1. Malaria prevalence during the transmission season 2. Frequency of mutation in drug resistance genes
Trial Locations
- Locations (1)
Tropical Medicine Research Institute
🇸🇩Khartoum, Sudan